To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2017 News Releases

About RSS

MSD submits application for approval of type-2 diabetes drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor

May 19, 2017

Tokyo, May 19, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that MSD has submitted an application for marketing approval of a combination drug of the DPP-4 inhibitor sitagliptin phosphate hydrate (brand name: JANUVIA® Tablets) and the SGLT2 inhibitor ipragliflozin L-Proline (brand name: Suglat® Tablets) for the treatment of type-2 diabetes in Japan.

 

JANUVIA® Tablet is the first selective DPP-4 inhibitor in Japan manufactured and marketed by MSD. This once-daily inhibitor selectively inhibits DPP-4 and increases the active incretin levels, thus demonstrating glucose-dependent glucose-lowering effect. Suglat® Tablet is the first selective SGLT2 inhibitor in Japan manufactured and marketed by Astellas. With once-daily administration, it selectively inhibits SGLT2 and blocks renal glucose reuptake, thus demonstrating non-insulin-dependent glucose-lowering effect. The combination of these two drugs with different mechanisms of action for the treatment of type-2 diabetes is expected to reduce patients’ burden of taking drugs and improve their adherence. In a clinical study conducted to support this application, the drug has shown efficacy, safety and tolerability.

 

MSD and Astellas look forward to further contributing to the treatment of diabetes by offering a new treatment option for type-2 diabetes patients who have difficulty controlling blood sugar levels with monotherapy.

 

###

 

 

Printer-friendly version


Main Text end
Local Navigation
Local Navigation end
Related Links